KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue: 2011-2017

Historic Current Deferred Revenue for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2017 value amounting to $287,000.

  • Supernus Pharmaceuticals' Current Deferred Revenue rose 37.32% to $287,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $287,000, marking a year-over-year increase of 37.32%. This contributed to the annual value of $287,000 for FY2017, which is 37.32% up from last year.
  • According to the latest figures from FY2017, Supernus Pharmaceuticals' Current Deferred Revenue is $287,000, which was up 37.32% from $209,000 recorded in FY2016.
  • Supernus Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $287,000 during FY2017, with a 5-year trough of $143,000 in FY2014.
  • For the 3-year period, Supernus Pharmaceuticals' Current Deferred Revenue averaged around $224,000, with its median value being $209,000 (2016).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Current Deferred Revenue slumped by 59.84% in 2013 and then spiked by 37.32% in 2017.
  • Over the past 5 years, Supernus Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $204,000 in 2013, then declined by 29.90% to $143,000 in 2014, then rose by 23.08% to $176,000 in 2015, then grew by 18.75% to $209,000 in 2016, then skyrocketed by 37.32% to $287,000 in 2017.